Your browser doesn't support javascript.
loading
Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study.
Iida, Megan A; Farrell, Kurt; Walker, Jamie M; Richardson, Timothy E; Marx, Gabriel A; Bryce, Clare H; Purohit, Dushyant; Ayalon, Gai; Beach, Thomas G; Bigio, Eileen H; Cortes, Etty P; Gearing, Marla; Haroutunian, Vahram; McMillan, Corey T; Lee, Edward B; Dickson, Dennis W; McKee, Ann C; Stein, Thor D; Trojanowski, John Q; Woltjer, Randall L; Kovacs, Gabor G; Kofler, Julia K; Kaye, Jeffrey; White, Charles L; Crary, John F.
Afiliación
  • Iida MA; Department of Pathology, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine At Mount Sinai, Friedman Brain Institute, Neuropathology Brain Bank & Research CoRE, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.
  • Farrell K; Department of Pathology, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine At Mount Sinai, Friedman Brain Institute, Neuropathology Brain Bank & Research CoRE, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.
  • Walker JM; Department of Pathology and Laboratory Medicine and The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.
  • Richardson TE; Department of Pathology and Laboratory Medicine and The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX, USA.
  • Marx GA; Department of Pathology, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine At Mount Sinai, Friedman Brain Institute, Neuropathology Brain Bank & Research CoRE, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.
  • Bryce CH; Department of Pathology, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine At Mount Sinai, Friedman Brain Institute, Neuropathology Brain Bank & Research CoRE, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.
  • Purohit D; Department of Pathology, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine At Mount Sinai, Friedman Brain Institute, Neuropathology Brain Bank & Research CoRE, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.
  • Ayalon G; Ultragenyx Pharmaceuticals, Novato, CA, USA.
  • Beach TG; Banner Sun Health Research Institute, Sun City, AZ, USA.
  • Bigio EH; Department of Pathology, Northwestern Cognitive Neurology and Alzheimer Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Cortes EP; Department of Pathology, Nash Family Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine At Mount Sinai, Friedman Brain Institute, Neuropathology Brain Bank & Research CoRE, 1 Gustave L. Levy Place Box 1194, New York, NY, 10029, USA.
  • Gearing M; Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Haroutunian V; Departments of Psychiatry and Neuroscience, Alzheimer's Disease Research Center, Icahn School of Medicine At Mount Sinai, New York, NY, USA.
  • McMillan CT; JJ Peters VA Medical Center (MIRECC), Bronx, NY, USA.
  • Lee EB; Department of Neurology, Perelman School of Medicine, Penn FTD Center, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, PA, USA.
  • Dickson DW; Department of Pathology and Laboratory Medicine, Translational Neuropathology Research Laboratory, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • McKee AC; Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
  • Stein TD; Department of Pathology, VA Medical Center & Boston University School of Medicine, Boston, MA, USA.
  • Trojanowski JQ; Department of Pathology, VA Medical Center & Boston University School of Medicine, Boston, MA, USA.
  • Woltjer RL; Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Kovacs GG; Department of Pathology, Oregon Health Sciences University, Portland, OR, USA.
  • Kofler JK; Laboratory Medicine Program, Krembil Brain Institute University Health Network Toronto Ontario, Ontario, Canada.
  • Kaye J; Department of Laboratory Medicine and Pathobiology, Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.
  • White CL; Institute of Neurology, Medical University of Vienna, Vienna, Austria.
  • Crary JF; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Acta Neuropathol Commun ; 9(1): 134, 2021 08 05.
Article en En | MEDLINE | ID: mdl-34353357
ABSTRACT
Primary age-related tauopathy (PART) is a form of Alzheimer-type neurofibrillary degeneration occurring in the absence of amyloid-beta (Aß) plaques. While PART shares some features with Alzheimer disease (AD), such as progressive accumulation of neurofibrillary tangle pathology in the medial temporal lobe and other brain regions, it does not progress extensively to neocortical regions. Given this restricted pathoanatomical pattern and variable symptomatology, there is a need to reexamine and improve upon how PART is neuropathologically assessed and staged. We performed a retrospective autopsy study in a collection (n = 174) of post-mortem PART brains and used logistic regression to determine the extent to which a set of clinical and neuropathological features predict cognitive impairment. We compared Braak staging, which focuses on hierarchical neuroanatomical progression of AD tau and Aß pathology, with quantitative assessments of neurofibrillary burden using computer-derived positive pixel counts on digitized whole slide images of sections stained immunohistochemically with antibodies targeting abnormal hyperphosphorylated tau (p-tau) in the entorhinal region and hippocampus. We also assessed other factors affecting cognition, including aging-related tau astrogliopathy (ARTAG) and atrophy. We found no association between Braak stage and cognitive impairment when controlling for age (p = 0.76). In contrast, p-tau burden was significantly correlated with cognitive impairment even when adjusting for age (p = 0.03). The strongest correlate of cognitive impairment was cerebrovascular disease, a well-known risk factor (p < 0.0001), but other features including ARTAG (p = 0.03) and hippocampal atrophy (p = 0.04) were also associated. In contrast, sex, APOE, psychiatric illness, education, argyrophilic grains, and incidental Lewy bodies were not. These findings support the hypothesis that comorbid pathologies contribute to cognitive impairment in subjects with PART. Quantitative approaches beyond Braak staging are critical for advancing our understanding of the extent to which age-related tauopathy changes impact cognitive function.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Encéfalo / Trastornos Cerebrovasculares / Ovillos Neurofibrilares / Proteínas tau / Tauopatías / Disfunción Cognitiva Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Commun Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Encéfalo / Trastornos Cerebrovasculares / Ovillos Neurofibrilares / Proteínas tau / Tauopatías / Disfunción Cognitiva Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Commun Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos